Ask AI
ProCE Banner Activity

Navigating Your Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Journey: A Patient -Provider Communication Checklist

PDF

Download this brief resource for your patients with essential thrombocythemia or polycythemia vera to help them understand their disease better through reliable resources of information plus an expert curated checklist of key questions designed to help align goals and treatment plans.

Released: March 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for hematologists and other healthcare professionals caring for patients with essential thrombocythemia and polycythemia vera.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify and evaluate thrombotic presentations that may be indicative of underlying ET or PV.

  • Apply best practices in ET and PV diagnosis, including appropriate use of bone marrow biopsy and molecular testing for accurate subtype classification

  • Utilize prognostic scoring systems and immune biomarker data (e.g., Triple A model, MIPSS-ET, MIPSS-PV) to assess thrombotic risk and guide personalized treatment planning.

  • Implement shared decision-making strategies to align treatment goals with patient values, literacy levels, and logistical needs

  • Prepare to integrate emerging second-line therapies into clinical practice for patients with ET or PV who are intolerant or resistant to front-line therapy.

Disclosure

Primary Author

Pankit Vachhani, MD: consultant/advisor/speaker: AbbVie, Amgen, Blueprint Medicines, Cogent Biosciences, DISC Medicine, Genentech, Geron, GSK, Incyte, Kartos, Karyopharm, Merck, Novartis, Pfizer, Servier, Silence Therapeutics, Sobi, Stemline, Syndax, Takeda.